MARKET

ENTA

ENTA

Enanta Pharmaceuticals Inc
NASDAQ
13.89
+0.31
+2.28%
After Hours: 13.89 0 0.00% 17:22 01/07 EST
OPEN
13.58
PREV CLOSE
13.58
HIGH
13.98
LOW
13.43
VOLUME
197.38K
TURNOVER
--
52 WEEK HIGH
17.15
52 WEEK LOW
4.090
MARKET CAP
400.90M
P/E (TTM)
-3.6190
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENTA last week (1229-0102)?
Weekly Report · 2d ago
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Barchart · 2d ago
Weekly Report: what happened at ENTA last week (1222-1226)?
Weekly Report · 12/29/2025 09:42
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?
NASDAQ · 12/26/2025 13:42
Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains?
NASDAQ · 12/22/2025 14:17
Weekly Report: what happened at ENTA last week (1215-1219)?
Weekly Report · 12/22/2025 09:42
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Simply Wall St · 12/20/2025 12:32
Weekly Report: what happened at ENTA last week (1208-1212)?
Weekly Report · 12/15/2025 09:46
More
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

Webull offers Enanta Pharmaceuticals Inc stock information, including NASDAQ: ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.